研究者詳細 - 寺井　崇二

Hematopoiesis-dependent expression of CD44 in murine hepatic progenitor cells 査読

Shinya Ohata, Makiko Nawa, Takeshi Kasama, Tokiwa Yamasaki, Kenji Sawanobori, Shoji Hata, Takashi Nakamura, Yoichi Asaoka, Toshio Watanabe, Hitoshi Okamoto, Takahiko Hara, Shuji Terai, Isao Sakaida, Toshiaki Katada, Hiroshi Nishina

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 379 ( 4 ) 817 - 823 2009年2月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：ACADEMIC PRESS INC ELSEVIER SCIENCE

The fetal liver serves as the predominant hematopoietic organ until birth. However, the mechanisms underlying this link between hematopoiesis and hepatogenesis are unclear. Previously, we reported the isolation of a monoclonal antibody (anti-Liv8) that specifically recognizes an antigen (Liv8) present in murine fetal livers at embryonic day 11.5 (E11.5). Liv8 is a cell surface molecule expressed by hematopoietic cells in both fetal liver and adult mouse bone marrow. Here, we report that Liv8 is also transiently expressed by hepatoblasts at E11.5. Using protein purification and mass spectrometry, we have identified Liv8 as the CD44 protein. Interestingly, the expression of Liv8/CD44 in fetal liver was completely lost in AML1(-/-) murine embryos, which lack definitive hematopoiesis. These results show that hepatoblasts change from Liv8/CD44-negative to Liv8/CD44-positive status in a hematopoiesis-dependent manner by E11.5, and indicate that Liv8/CD44 expression is an important link between hematopoiesis and hepatogenesis during fetal liver development. (C) 2008 Elsevier Inc. All rights reserved.

DOI： 10.1016/j.bbrc.2008.12.149

On a diagnostic imaging teaching system for endoscopic education 査読

K. Ogashiwa, Y. Hamamoto, Y. Fujita, K. Murokawa, H. Yoneda, M. Saito, S. Terai, I. Sakaida

Proceedings of 1st Asia Pacific Conference on Health Promotion and Education 2009年1月

Continuos intravenous infusion of atrial natriuretic peptide(ANP) prevented liver fibrosis in rat 査読

Noriko Ishigaki, Naold Yamamoto, Haiyan Jin, Kouichi Uchida, Shuji Terai, Isao Sakaida

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 378 ( 3 ) 354 - 359 2009年1月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：ACADEMIC PRESS INC ELSEVIER SCIENCE

The atrial natriuretic peptide (ANP) are used as the acute heart failure treatment in clinical and reported the suppression of fibrosis in the heart, lung recently. The aim of this Study was to analyze the suppressive effect of liver fibrosis about ANP. In vitro, rat hepatic stellate cell line (HSC-T6) were treated with ANP. In vivo, Wister rats were injected with dimethylnitrosamine (DMN) twice a week via intra-peritoneal for 4 weeks. ANP group was given by continuance intravenous dosage system used 24 h infusion pump for 3 weeks after 1 week of DMN administration. In vitro, ANP suppressed alpha-SMA expression and was inhibited the growth of HSC, and reduced the expression of type 1 procollagen, TIMP-1, -2 expression. In vivo, The ANP group showed lower serum AST, ALT, HA level. Liver fibrosis was suppressed by ANP. ANP also decreased gene expression of type 1 procollagen, TIMP-1, -2 and alpha-SMA, TGF-beta 1 expression. Our results showed that continuous ANP infusion has the specific capacity of inhibiting HSC activation and protecting hepatocytes and the useful capacity to suppress the liver fibrosis. (C) 2008 Published by Elsevier Inc.

DOI： 10.1016/j.bbrc.2008.10.154

肝硬変症に対する自己骨髄細胞投与療法の現状と今後の展望

寺井崇二, 坂井田功

日本医科大学医学会雑誌 5 ( 1 ) 27 - 32 2009年

Current status of autologous bone marrow cell infusion therapy for liver cirrhosis patients 査読

Shuji Terai, Isao Sakaida

HEPATOLOGY RESEARCH 38 S72 - S75 2008年11月

記述言語：英語出版者・発行元：WILEY-BLACKWELL PUBLISHING, INC

This article reviews recent translational research on the development of cell therapy using autologous bone marrow cell for liver cirrhosis patients. A clinical study of autologous bone marrow cell infusion (ABMI) therapy for liver cirrhosis patient was begun on Nov. 14, 2003. We previously reported nine liver cirrhosis (LC) cases that underwent ABMI from the peripheral vein and followed their progress up to 24 weeks. Subjects were LC patients with total bilirubin TB of < 3.0 mg/dL, platelets > 5 (10(10)/L) and no viable hepatocellular carcinoma on diagnostic imaging. Mononuclear cells (MNCs) were separated by cell washing and were infused via the peripheral vein. After ABMI therapy liver function and Child-Pugh Score were significantly improved at 4 weeks and 24 weeks (P < 0.05). A total of 23 cases of ABMI therapy have been performed for LC patients to date. No major adverse effects were noted due to ABMI therapy. In conclusion, ABMI therapy should be considered as a novel treatment for LC patients.

DOI： 10.1111/j.1872-034X.2008.00430.x

Relation between serum levels of cell-free DNA and inflammation status in hepatitis C virus-related hepatocellular carcinoma 査読

Michihisa Iida, Norio Iizuka, Isao Sakaida, Toyoki Moribe, Nozomi Fujita, Toshiaki Miura, Shigeru Tamatsukuri, Hideo Ishitsuka, Koichi Uchida, Shuji Terai, Yoshihiro Tokuhisa, Kazuhiko Sakamoto, Takao Tamesa, Takanobu Miyamoto, Yoshihiko Hamamoto, Masaaki Oka

ONCOLOGY REPORTS 20 ( 4 ) 761 - 765 2008年10月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：SPANDIDOS PUBL LTD

Our study revealed that the level of circulating cell-free DNA (cfDNA) is increased in the serum of patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). To gain insight into the mechanism underlying this phenomenon, we examined the association between cfDNA levels and various clinicopathological factors in 96 patients with HCV-related HCC and 99 non-HCC patients with HCV. Using pooled DNA microarray data, we profiled the expression patterns of inflammatory cytokine genes in 14 primary tumors from the group of HCC patients. We found that there were positive associations between the cfDNA level, aspartate aminotransferase levels and the number of leukocytes and neutrophils in patients with HCV-related HCC but not in non-HCC patients with HCV. The serum cfDNA level was not associated with other clinicopathological factors in HCC or non-HCC patients. A cluster analysis based on the inflammatory cytokine gene data revealed that HCCs with a high serum cfDNA level had increased levels of several inflammatory cytokine genes, suggesting that the serum cfDNA level is associated with the inflammatory status in primary tumors in HCV-related HCC.

DOI： 10.3892/or_00000071

生活習慣病合併肝癌患者におけるHeat shock proteinおよび小胞体ストレス関連分子の発現の検討

消化器疾患の分子遺伝学的病態 HGF/c-Met signalingによるredox homeostasisの維持が肝発癌増殖を抑制する

高見太郎, 寺井崇二, 坂井田功

日本消化器病学会雑誌 105 ( 臨増大会 ) A672 - A672 2008年9月

Hepatocyte growth factor/c-met signaling pathwayの欠損はDEN誘発肝発癌早期段階を促進させる(Loss of hepatocyte growth factor/c-met signaling pathway accelerates early stages of DEN-induced hepatocarcinogenesis)

高見太郎, 内田耕一, 寺井崇二, 坂井田功

日本癌学会総会記事 67回 179 - 179 2008年9月

大石俊之, 寺井崇二, 桑代紳哉, 松本俊彦, 坂井田功

肥満研究 14 ( Suppl. ) 202 - 202 2008年9月

メダカNASHモデルを用いた治療剤開発のストラテジー

寺井崇二, 桑代紳哉, 大石俊之, 松本俊彦, 坂井田功

肥満研究 14 ( Suppl. ) 189 - 189 2008年9月

メダカNASHモデルを用いたTelmisartanの効果検討

桑代紳哉, 寺井崇二, 大石俊之, 松本俊彦, 坂井田功

肥満研究 14 ( Suppl. ) 235 - 235 2008年9月

Pilot study of combination therapy with transcatheter arterial infusion chemotherapy using iodized oil and percutaneous radiofrequency ablation during occlusion of hepatic blood flow for hepatocellular carcinoma 査読

Ryt Shiraishi, Takahiro Yamasaki, Issei Saeki, Kohsuke Ok-Ita, Ytthki Yamaguchi, Koichi Uchida, Shuji Terai, Isao Salfaida

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 31 ( 4 ) 311 - 316 2008年8月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：LIPPINCOTT WILLIAMS & WILKINS

Objective: We have reported that radiofrequency (RF) ablation with balloon Occlusion of the hepatic artery (balloon-occluded RF ablation) increases the Coagulation area compared with standard RF ablation. In this study, We evaluated the efficacy and safety of combination therapy with transcatheter arterial infusion chemotherapy (TAI) using iodized oil and balloon-occluded RF ablation in patients with hepatocellular carcinoma
Patients and Methods: We studied 12 patients with 12 HCC nodules (mean tumor diameter, 27.3 mm). All patients were classified as Child-Pugh Class A. Immediately after TAI using iodized oil, we performed balloon-occluded RF ablation.
Results: One treatment session of the combination therapy was done for 10 of 12 nodules (83%). The greatest long-axis and short-axis dimensions of the area coagulated after the combination therapy were 48.8 +/- 5.5 mm and 41.9 +/- 4.1 mm, respectively. During follow-up (mean, 33.4 months), there was no local recurrence. The 1, 2, and 3-year survival rates were 100%, 92%, and 83%, respectively. No fatal complications were observed.
Conclusions: The combination therapy is an effective and safe treatment Under favorable liver reserve capacity. Using the combination therapy, it is possible to finish one treatment session for patients with HCC nodules measuring less than 3 cm in greatest dimension.

DOI： 10.1097/COC.0b013e31815e4539